%0 Journal Article %1 LUO2023216218 %A Luo, Hongmei %A Feng, Yu %A Wang, Fangfang %A Lin, Zhimei %A Huang, Jingcao %A Li, Qian %A Wang, Xin %A Liu, Xiang %A Zhai, Xinyu %A Gao, Qianwen %A Li, Lingfeng %A Zhang, Yue %A Wen, Jingjing %A Zhang, Li %A Niu, Ting %A Zheng, Yuhuan %D 2023 %J Cancer Letters %K ivermectin myeloma %P 216218 %R https://doi.org/10.1016/j.canlet.2023.216218 %T Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma %U https://www.sciencedirect.com/science/article/pii/S0304383523001696 %V 565 %X Multiple myeloma (MM) is an incurable malignancy of plasma cells. Ivermectin is a US Food and Drug Administration-approved drug for antiparasitic use. Here, we showed that ivermectin exerted anti-MM effects and significantly synergized with proteasome inhibitors in vitro and in vivo. Ivermectin alone exhibited mild anti-MM activity in vitro. Further investigation suggested that ivermectin inhibited proteasome activity in the nucleus by repressing the nuclear import of proteasome subunits, such as PSMB5-7 and PSMA3-4. Therefore, ivermectin treatment caused the accumulation of ubiquitylated proteins and the activation of the UPR pathway in MM cells. Furthermore, ivermectin treatment caused DNA damage and DNA damage response (DDR) signaling pathway activation in MM cells. Ivermectin and bortezomib exhibited synergized anti-MM activity in vitro. The dual-drug treatment resulted in synergistic inhibition of proteasome activity and increased DNA damage. An in vivo study using a human MM cell line xenograft mouse model showed that ivermectin and bortezomib efficiently repressed MM tumor growth in vivo, while the dual-drug treatment was well tolerated by experimental animals. Overall, our results demonstrated that ivermectin alone or cotreated with bortezomib might be promising in MM treatment.

@article{LUO2023216218, abstract = {Multiple myeloma (MM) is an incurable malignancy of plasma cells. Ivermectin is a US Food and Drug Administration-approved drug for antiparasitic use. Here, we showed that ivermectin exerted anti-MM effects and significantly synergized with proteasome inhibitors in vitro and in vivo. Ivermectin alone exhibited mild anti-MM activity in vitro. Further investigation suggested that ivermectin inhibited proteasome activity in the nucleus by repressing the nuclear import of proteasome subunits, such as PSMB5-7 and PSMA3-4. Therefore, ivermectin treatment caused the accumulation of ubiquitylated proteins and the activation of the UPR pathway in MM cells. Furthermore, ivermectin treatment caused DNA damage and DNA damage response (DDR) signaling pathway activation in MM cells. Ivermectin and bortezomib exhibited synergized anti-MM activity in vitro. The dual-drug treatment resulted in synergistic inhibition of proteasome activity and increased DNA damage. An in vivo study using a human MM cell line xenograft mouse model showed that ivermectin and bortezomib efficiently repressed MM tumor growth in vivo, while the dual-drug treatment was well tolerated by experimental animals. Overall, our results demonstrated that ivermectin alone or cotreated with bortezomib might be promising in MM treatment.}, added-at = {2024-03-14T08:52:00.000+0100}, author = {Luo, Hongmei and Feng, Yu and Wang, Fangfang and Lin, Zhimei and Huang, Jingcao and Li, Qian and Wang, Xin and Liu, Xiang and Zhai, Xinyu and Gao, Qianwen and Li, Lingfeng and Zhang, Yue and Wen, Jingjing and Zhang, Li and Niu, Ting and Zheng, Yuhuan}, biburl = {https://www.bibsonomy.org/bibtex/2af2ac276463266c215817208e6e72936/fordham1}, description = {Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma - ScienceDirect}, doi = {https://doi.org/10.1016/j.canlet.2023.216218}, interhash = {8e4f6404bc81ffcc146e8c4e4ef50666}, intrahash = {af2ac276463266c215817208e6e72936}, issn = {0304-3835}, journal = {Cancer Letters}, keywords = {ivermectin myeloma}, pages = 216218, timestamp = {2024-03-14T08:56:21.000+0100}, title = {Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma}, url = {https://www.sciencedirect.com/science/article/pii/S0304383523001696}, volume = 565, year = 2023 }